Meena R Chandok

US Patent:

20100331391, Dec 30, 2010

Filed:

Sep 10, 2008

Appl. No.:

12/733636

Inventors:

Meena Chandok - Odenton MD, US
Donna Farber - Baltimore MD, US
Francesca Okoye - Menlo Park CA, US

International Classification:

A61K 31/713
C12Q 1/02
C12N 5/0783
A61K 31/05
A61P 37/06

US Classification:

514 44 A, 435 29, 435375, 514733

Abstract:

In this application is described a novel, multiparameter analysis of TCR-coupled signaling and function in resting and activated naive and memory CD4 T cells, revealing a biochemical basis for immunological recall. Results reveal a novel biochemical signature imparted to memory CD4 T cells enabling efficacious responses through increased ZAP-70 expression and reduced accumulation of downstream signaling events.

US Patent:

20220347267, Nov 3, 2022

Filed:

Sep 17, 2020

Appl. No.:

17/761077

Inventors:

- Rockville MD, US
Marika Magdelena Smith - Rockville MD, US
Meena Chandok - Rockville MD, US
Senthamil Selvan - Rockville MD, US
William Murphy - Rockville MD, US
Palak Parekh - Rockville MD, US

International Classification:

A61K 38/19
G01N 33/574
A61P 37/02

Abstract:

The present invention provides methods to improve a cancer patient's response to immune checkpoint inhibitor (ICI) therapy, and functional test to predict likelihood of response. Specifically, the invention provides methods to improve patient's response to immune checkpoint inhibitors using modulators and to predict response to the combination of immune checkpoint inhibitors and modulators.

US Patent:

20220339257, Oct 27, 2022

Filed:

Sep 17, 2020

Appl. No.:

17/761461

Inventors:

- Rockville MD, US
Meena Chandok - Rockville MD, US
William Murphy - Rockville MD, US
Gregory Botting - Rockville MD, US
Palak Parekh - Rockville MD, US
Senthamil Selvan - Rockville MD, US

International Classification:

A61K 38/21
A61K 38/19
A61K 38/18
A61K 38/20
A61P 35/00
A61K 31/517
G01N 33/574

Abstract:

This invention relates to methods of increasing the sensitivity of tumors to anti cancer therapies including antibody therapy, chemotherapy, radiotherapy, and therapies targeting cell signaling pathways such as the MAPK and PI3K pathways and receptor tyrosine kinases (e.g. EGFR). By increasing sensitivity of tumors to these agents, this invention will: (a)Prolong response in already responsive subjects; (b) Increase response rates by converting non-responsive patients into responsive patients; (c) Reverse treatment-induced resistance of tumors to anticancer therapy; and (d) Decrease treatment-associated toxicities by decreasing therapy dosages required for response. The invention also describes predictive tests, to identify patients most likely to respond to the combination treatments.